momelotinib,danazol
sierra oncology
['#myelof', 'momentum', 'mpnsm', '#mpn', 'momelotinib']
congress #asco22 | discusses the momentum phase iii trial of momelotinib vs danazol in patients with #myelofibrosis n=124. tss response rate (plt 150x10^9/l) was 29.6% in momelotinib group vs 11.6% in the danazol group at week 24 #mpnsm #mpn 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm